Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 7, 2005, Pages 4047-4050

  Castagna, Maria Grazia ^a   Pinchera, Aldo ^a   Marsili, Alessandro ^a   Giannetti, Monica ^a   Molinaro, Eleonora ^a   Fierabracci, Paola ^a   Grasso, Lucia ^a   Pacini, Furio ^b   Santini, Ferruccio ^a   Elisei, Rossella ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROTROPIN;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY HEIGHT; BODY MASS; BODY SURFACE; BODY WEIGHT; CANCER PATIENT; CONTROLLED STUDY; FEMALE; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OBESITY; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL ANALYSIS; STIMULATION; THYROID CARCINOMA; THYROTROPIN BLOOD LEVEL; TIME;

BODY COMPOSITION; BODY MASS INDEX; FEMALE; HUMANS; MALE; OBESITY; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROTROPIN;

EID: 23044507514     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2005-0534     Document Type: Article

References (20)

1. Morgan DJ, Bray KM 1994 Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 26:292-307
2. Roubenoff R, Kehayas JJ 1991 The meaning and measurement of lean body mass. Nutr Rev 49:163-175
3. Roberts CJ, Jackson L, Halliwell M, Branch RA 1976 The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man. Br J Clin Pharmacol 3:907-913
4. Ladenson PW, Braverman LE, Mazzaferri EL, Bruker-Davis F, Cooper DS, Garber JR, Wondsford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD 1997 Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337:888-896
5. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Rossi DS, Luster M, Samuels MH, Becker DV, Maxon 3rd HR, Cavalieri RR, Spencer C, MecEllin K, Weintraub BD, Ridgway EC 1999 A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-3885
6. Robbins RJ, Tuttle RM, Sonenberg M, Shaha A, Sharaf R, Robbins H, Fleisher M, Larson SM 2001 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 11:865-869
7. 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87:4063-4068
8. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, pasquini C, Piazza F, Caciagli M, Mariani GJ 2003 Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in l-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 88:4110-4115
9. Pacini F, Ladenson P, Schlumberger M, Driedger A, Kloos R, Sherman S, Corone C, Haugen B, Reiners C 2004 Preparation with thyrotropin is equivalent to thyroid hormone withdrawal as preparation for thyroid remnant ablation in differentiated thyroid carcinoma. Turk J Endocrinol Metab 8(Suppl 1):21
10. Vitale G, Lupoli GA, Ciccarelli A, Lucariello A, Fittipaldi MR, Fonderico F, Panico A Luppoli G 2003 Influence of body surface area on serum peak thyrotropin (TSH) levels after recombinant human TSH administration. J Clin Endocrinol Metab 88:1319-1322
11. Thotakura NR, Desai RK, Bates LG, Cole ES, Pratt BM, Weintraub BD 1991 Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology 128:341-348
12. Sartorio A, Spada A, Morabito F, Faglia G 1988 Different responsiveness to repeated GHRH administration in normal children and adults. J Endocrinol Invest 11:727-729
13. Shaikh S, Mahakanasib D, Chatterjee S, Kupard AV, Khaled MA 2003 Lean body mass in preschool aged urban children in India: gender difference. Eur J Clin Nutr 57:389-393
14. Logue JP, Tsang RW, Brierley JD, Simpson WJ 1994 Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome. Br J Radiol 67:1127-1131
15. Arad E, O'Mara RE, Wilson GA 1993 Ablation of remaining functioning thyroid lobe with radioiodine after hemithyroidectomy for carcinoma. Clin Nucl Med 18:662-663
16. Samuel AM, Rajashekharrao B 1994 Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med 35:1944-1950
17. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433-1441
18. Luster M, Lassman M, Haenscheid H, Mikalowski U, Incerti C, Reiners C 2000 Use of recombinant human thyrotrophin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 85:3640-3645
19. Lippi F, Capezzone M, Angelini F, Taddei D, Molinaro E, Pinchera A, Pacini F 2001 Radioiodine treatment of metastatic differentiated thyroid cancer in patients on l-thyroxine, using recombinant human TSH. Eur J Endocrinol 144:5-11
20. de Keizer B, Brans B, Hoekstra A, Zelissen PM, Koppeschaar HP, Lips CJ, van Rijk PP, Dierckx RA, de Klerk JM 2002 Tumor dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur J Nucl Med Mol Imag 30:367-373